1 January 2026 – 30 June 2026 (unaudited)
Attributable to shareholders of PolyPeptide Group AG:
|
|
|
|
|
|
|
|
|
|
kEUR |
Share capital |
Share premium |
Translation reserve |
Treasury shares |
Other capital reserves |
Retained earnings |
Total |
|
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2026 |
302 |
203,129 |
20,976 |
-6,466 |
31 |
122,626 |
340,598 |
|
|
|
|
|
|
|
|
|
|
Result for the period |
|
|
|
|
|
9,081 |
9,081 |
|
Remeasurement gain / (loss) on defined benefit plans, net of tax |
|
|
|
|
|
99 |
99 |
|
Currency exchange differences |
|
|
-568 |
|
|
|
-568 |
|
Total comprehensive income |
– |
– |
-568 |
– |
– |
9,180 |
8,612 |
|
|
|
|
|
|
|
|
|
|
Share-based payment |
|
|
|
|
2,004 |
|
2,004 |
|
Transfer of own shares |
|
|
|
650 |
-650 |
|
– |
|
Total transactions with owners |
– |
– |
– |
650 |
1,354 |
– |
2,004 |
|
Balance as at 30 June 2026 |
302 |
203,129 |
20,408 |
-5,816 |
1,385 |
131,806 |
351,214 |
1 January 2025 – 30 June 2025 (unaudited)
Attributable to shareholders of PolyPeptide Group AG:
|
|
|
|
|
|
|
|
|
|
kEUR |
Share capital |
Share premium |
Translation reserve |
Treasury shares |
Other capital reserves |
Retained earnings |
Total |
|
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2025 |
302 |
203,129 |
21,309 |
-8,398 |
425 |
140,477 |
357,244 |
|
|
|
|
|
|
|
|
|
|
Result for the period |
|
|
|
|
|
-26,539 |
-26,539 |
|
Remeasurement gain / (loss) on defined benefit plans, net of tax |
|
|
|
|
|
2,240 |
2,240 |
|
Currency exchange differences |
|
|
-2,437 |
|
|
|
-2,437 |
|
Total comprehensive income |
– |
– |
-2,437 |
– |
– |
-24,299 |
-26,736 |
|
|
|
|
|
|
|
|
|
|
Purchase of own shares |
|
|
|
-484 |
|
|
-484 |
|
Share-based payment |
|
|
|
|
961 |
|
961 |
|
Transfer of own shares |
|
|
|
1,429 |
-1,429 |
|
– |
|
Total transactions with owners |
– |
– |
– |
945 |
-468 |
– |
477 |
|
Balance as at 30 June 2025 |
302 |
203,129 |
18,872 |
-7,453 |
-43 |
116,178 |
330,985 |